Oncology Conferences in 2026: A Complete Guide for Healthcare Industry Leaders
The oncology conference calendar in 2026 is substantial, and for healthcare industry leaders in pharma, health tech, medical devices, or healthcare services, the challenge is selecting the right combination of them and understanding what each format is actually built to deliver.
Some events are designed to advance science, while others exist to move commercial strategy. A third category, smaller in number but often higher in value for industry participants, is built around direct, closed-door access to the health system executives who govern oncology service lines, set formulary policy, and make the purchasing decisions that determine whether a product gains traction in the market.
This guide covers the full spectrum of the 2026 oncology conference circuit, beginning with the events that offer that level of access, and then moving through the broader calendar of strategic, commercial, and clinical meetings that merit a place in your annual planning.
The Best Oncology Conferences of 2026
THMA Spring Oncology Forum 2026
Dates and Location: May 6-8, 2026 | Fort Lauderdale, FL
Who It Is For: Pharma commercial leaders, account management teams, and market access executives who need direct engagement with the health system oncology decision-makers who influence pathway inclusion, formulary positioning, and clinical implementation.
Why It Stands Out in 2026: Today's oncology market is shaped by tightening access controls, accelerating therapeutic innovation, growing pressure around value demonstration, and increasing administrative friction between manufacturers and health systems. The THMA Oncology Forum places pharma and health tech companies in the same room as senior Oncology Service Line Executives from nationally recognized systems including Mayo Clinic, Yale New Haven Health, Northwell Health, Cleveland Clinic, Cedars-Sinai, and Mass General Brigham, among others.
Attendance is kept deliberately small. The format is retreat-style, and the structure maintains a strict 1:1 health system-to-industry ratio to ensure conversation remains substantive rather than transactional. Recent forum topics have included pathway governance and prescribing behavior, ambulatory infusion and cell therapy program development, and precision oncology partnership models. These are not panel discussions with prepackaged answers. They are closed-door peer conversations that surface the unfiltered operational and strategic realities that drive health system oncology decisions.
Best Suited For: Pharma commercial, market access, and field leadership teams that need validated, provider-level intelligence to sharpen launch strategy, pull-through planning, or account engagement. Also relevant for health tech companies whose solutions intersect with oncology operations, care navigation, or clinical decision support.
THMA Fall Oncology Forum 2026
Dates and Location: September 16-18, 2026 | Boston, MA
Who It Is For: The same audience as the Spring Forum; pharma commercial leaders, market access teams, and health tech executives engaged with oncology service line strategy, with the added relevance for organizations whose fiscal year planning cycles or Q3/Q4 strategic reviews benefit from late-summer executive intelligence.
Why It Stands Out in 2026: The Fall Oncology Forum convenes the same caliber of health system oncology leadership as the spring gathering, with fresh member-driven content reflecting where the oncology landscape has moved in the intervening months. For organizations that find a single annual forum insufficient given the pace of market change in oncology, attending both forums provides a material advantage: two distinct snapshots of how health system strategy is evolving, separated by a full calendar quarter. The fall timing in Boston also positions this event well relative to the broader oncology scientific calendar, allowing industry teams to carry insights from ASCO and AACR into a setting where they can pressure-test those insights directly with the provider community.
Best Suited For: Companies with active oncology pipelines, commercial launches underway, or significant account relationships at major health systems that warrant sustained executive engagement throughout the year.
THMA Pharmacy Growth Collaborative 2026
Dates and Location: Spring: June 3-5, 2026 | Carlsbad, CA | Fall: October 14-16, 2026 | Boston, MA
Who It Is For: Industry leaders in pharma, specialty pharmacy, and healthcare services who are working to build or deepen relationships with health system pharmacy executives responsible for formulary management, specialty drug access, and pharmacy strategy across large integrated delivery systems.
Why It Stands Out in 2026: The policy environment around pharmacy is in active flux with 340B reform, Medicaid funding uncertainty, the downstream effects of the Inflation Reduction Act, and the evolving payer landscape for specialty products, all of which are reshaping how health system pharmacy leaders think about partnerships and operational priorities.
The Pharmacy Growth Collaborative brings industry executives into peer-level conversation with pharmacy leaders from the same nationally prominent health systems represented across THMA's broader community. The retreat-style format, twice-annual cadence, and member-driven agenda design mean that discussions reflect genuine institutional priorities rather than curated conference themes. Recent sessions have covered value-based care transformation, ambulatory infusion strategy, and the financial and operational implications of specialty pharmacy program development. The collaborative is currently accepting additional industry members seeking to contribute substantively to these conversations.
Best Suited For: Pharma companies managing specialty and oncology portfolios with health system formulary access as a central commercial challenge, as well as healthcare services and technology companies building in the pharmacy channel.
THMA CPE Circle 2026
Dates and Location: Spring: May 11-13, 2026 | Fort Lauderdale, FL | Fall: October 26-28, 2026 | Scottsdale, AZ
Who It Is For: CEOs, Chief Growth Officers, and strategic product leaders from healthcare technology, pharma, and services companies seeking direct relationships with Chief Physician Executives at major U.S. independent health systems.
Why It Stands Out in 2026: Chief Physician Executives sit at the intersection of clinical governance, physician alignment, operational transformation, and increasingly, technology adoption. They are among the most consequential decision-makers in health systems for companies whose solutions require physician buy-in, clinical workflow integration, or executive-level sponsorship, and they are among the hardest to reach through conventional conference channels.
The CPE Circle is a highly curated, intimate forum designed explicitly around their priorities, with member-led sessions addressing AI leadership in the clinical enterprise, CFO-CPE collaboration on shared ROI frameworks, navigating the new policy landscape, and physician alignment in an era of market disruption. The program carries continuing education accreditation and maintains a 1:1 health system-to-industry ratio. Attendees from organizations such as Baptist Health Care, Children's Minnesota, and Loma Linda University Health participate alongside select industry partners hand-chosen for their ability to contribute meaningfully rather than merely present.
Best Suited For: Industry companies whose commercial success depends on physician executive sponsorship and clinical adoption at the health system level, particularly in AI-enabled clinical tools, workforce solutions, and care delivery transformation.
ACCC 43rd National Oncology Conference 2026
Dates and Location: October 21, 2026 | Boston, MA (Omni Boston Hotel at the Seaport)
Who It Is For: The oncology care team, in its broadest definition, clinicians, administrators, advanced practice providers, navigators, patient advocates, and program leaders from community cancer centers and hospital-based oncology programs nationwide.
Why It Stands Out in 2026: The ACCC National Oncology Conference is the leading interdisciplinary professional development event for the cancer care community, organized by the Association of Cancer Care Centers, a network of more than 28,000 practitioners from 2,100 hospitals and practices. The conference consistently addresses the operational and clinical realities of community oncology, making it an unusually practical event for attendees focused on the implementation side of oncology care rather than its scientific frontiers.
The ACCC Innovator Awards, now in their fifteenth year, are presented at this conference, showcasing groundbreaking strategies from cancer programs across the country. THMA's team attends this conference as part of ongoing engagement with the oncology community, and industry leaders present here gain meaningful visibility across the community cancer center landscape.
Best Suited For: Pharma and health tech companies whose products or services operate within or need adoption by community oncology programs, as well as organizations focused on access, navigation, and care delivery solutions in the cancer space.
J.P. Morgan 44th Annual Healthcare Conference 2026
Dates and Location: January 12-15, 2026 | The Westin St. Francis, San Francisco, CA (This event has already taken place for 2026. It is included here for annual planning reference.)
Who It Is For: Healthcare executives, biopharma and health tech leadership teams, investors, and strategic development professionals across the full breadth of the industry.
Why It Stands Out in 2026: The J.P. Morgan Healthcare Conference is the largest healthcare investment symposium in the world, and its significance goes well beyond its official program. The week it occupies in San Francisco effectively functions as an industry-wide gathering point, with an extensive ecosystem of satellite events, executive dinners, bilateral meetings, and investor conversations running concurrently.
For oncology-focused companies, the conference is a critical venue for capital markets activity, strategic partnership exploration, and pipeline positioning. THMA's team engages with the healthcare industry at this conference and uses the surrounding week as a touchpoint with members and partners. Because the event is invitation-only through J.P. Morgan, industry participation requires a relationship with the firm or an alternative path into the week's programming.
Best Suited For: Executive leadership and business development teams at commercial-stage oncology companies, as well as companies preparing for fundraising, licensing discussions, or partnership formation in the healthcare sector.
AMCP Annual Meeting 2026
Dates and Location: April 13-16, 2026 | Music City Center, Nashville, TN
Who It Is For: Managed care pharmacy professionals, health plan and PBM decision-makers, pharmaceutical company market access teams, and healthcare consultants with an interest in how medications are accessed, paid for, and managed within organized health systems and payer frameworks.
Why It Stands Out in 2026: The AMCP Annual Meeting is the premier gathering for the managed care pharmacy community, drawing more than 4,000 professionals who govern formulary decisions, utilization management, and pharmacy benefit strategy across payers and health systems.
For oncology manufacturers, this conference represents direct access to the payer and pharmacy benefit management community that determines coverage policy, step therapy requirements, and prior authorization criteria for oncology products. The 2026 program features an AI pre-conference, main stage presentations, and an extensive expo, with educational sessions focused on real-world evidence, precision medicine, and emerging trends in managed care. THMA attends AMCP as part of its engagement with the broader pharmacy and market access landscape.
Best Suited For: Pharma market access, health economics, and payer affairs teams navigating formulary positioning and coverage strategy for oncology and specialty products.
Fierce Pharma Week 2026
Dates and Location: September 14-17, 2026 | Pennsylvania Convention Center, Philadelphia, PA
Who It Is For: Marketing, commercialization, medical affairs, PR and communications, and new product planning professionals from pharmaceutical and biotech companies.
Why It Stands Out in 2026: Fierce Pharma Week is the pharmaceutical industry's leading cross-functional conference for commercial and communications strategy, bringing together senior leaders across the disciplines that govern how products reach patients and sustain market presence. The 2025 inaugural event drew 3,000 attendees and featured more than 400 industry thought leaders from AbbVie, AstraZeneca, Bristol Myers Squibb, Johnson and Johnson, Pfizer, Regeneron, Takeda, and many others.
The 2026 edition at the Pennsylvania Convention Center is expected to build on that momentum with dedicated content tracks across pharma marketing, commercialization, and medical affairs. For oncology companies, the conference is particularly relevant for teams managing launch strategy, omnichannel engagement, and the increasingly complex intersection of commercial and medical functions. THMA monitors and engages with the Fierce Pharma community given the significant overlap between its audience and the pharma commercial leaders who participate in THMA programs.
Best Suited For: Pharma commercial, marketing, and medical affairs leadership from oncology-focused companies who need cross-functional perspectives on launch execution, brand strategy, and market engagement.
ASCO Annual Meeting 2026
Dates and Location: May 29 - June 2, 2026 | McCormick Place, Chicago, IL
Who It Is For: Oncologists, clinical researchers, scientists, patient advocates, healthcare professionals, and industry representatives from across the global cancer care community.
Why It Stands Out in 2026: The ASCO Annual Meeting is the most significant clinical oncology event in the world, drawing more than 40,000 professionals from over 100 countries. Presented by the American Society of Clinical Oncology, the five-day program encompasses more than 200 sessions covering the full spectrum of cancer research, from translational science and clinical trials to survivorship, advocacy, and health equity.
For pharmaceutical and health technology companies, ASCO is where pipeline data moves, treatment guidelines shift, and competitive intelligence is generated at scale. Abstract releases in May preceding the conference generate substantial scientific and investor attention before the meeting even begins. Both in-person and virtual attendance options are available.
Best Suited For: Medical affairs, clinical development, and scientific communication teams whose work is anchored in oncology clinical evidence, as well as commercial teams tracking competitive pipeline data and treatment landscape evolution.
AACR Annual Meeting 2026
Dates and Location: April 17-22, 2026 | San Diego Convention Center, San Diego, CA
Who It Is For: Cancer researchers, translational scientists, clinical investigators, and healthcare professionals engaged with the foundational and applied science of cancer biology, as well as industry participants in drug development and oncology innovation.
Why It Stands Out in 2026: Organized by the American Association for Cancer Research, the AACR Annual Meeting is the oncology scientific community's most prominent gathering for basic, translational, and clinical cancer research. Its scope runs from population science and cancer prevention through molecular biology, experimental therapeutics, and clinical trials, making it unusually broad in scientific coverage.
For industry teams, AACR is critical for tracking early-stage science, monitoring academic research that may shape future pipelines, and engaging with the scientific community at the frontier of oncology innovation. The accompanying AACR Oncology Industry Partnering Event runs concurrently, creating structured opportunities for business development and partnership activity alongside the scientific program.
Best Suited For: Medical affairs, early clinical development, and business development teams at oncology-focused companies whose strategies require deep engagement with the cancer research community and the science that precedes commercialization.
What to Look for in an Oncology Conference
Not all healthcare conferences are built the same way, and the criteria worth applying when evaluating them are more specific than most conference directories let on. The following are the attributes that separate high-value events from those that consume time without returning proportional insight or relationship capital.
Audience composition
The most important question is not how many people attend, but who they are. An event drawing 300 senior oncology service line executives from leading health systems will consistently outperform a trade show floor of 10,000 attendees in terms of the quality of conversation it makes possible. Look carefully at the attendee profile before committing budget and team time.
Access structure
Many conferences offer theoretically open networking, but the practical reality is that senior health system executives are difficult to reach in large, unstructured settings. Events that deliberately engineer access through structured facilitation, limited participant counts, or enforced ratios between health system and industry attendees, tend to deliver meaningfully different outcomes than those that do not.
Dialogue versus broadcast
Presentations and keynotes transfer information. Peer-led, member-driven discussions generate insight. The best events for industry leaders are those that prioritize the latter, because the intelligence that surfaces in candid executive conversation is not available anywhere else.
Topic relevance to current priorities
Oncology is moving fast across therapeutic innovation, pathway governance, value-based care model adoption, specialty pharmacy, and precision medicine infrastructure. An event whose agenda reflects the live priorities of health system oncology leaders is considerably more useful than one whose content lags the market by a year.
Continuity of relationship
A single event interaction is valuable. A sustained relationship with the same peer group across multiple years is exponentially more so. Programs that build membership community and reconvene the same participants regularly produce compounding returns on the investment of showing up.
Building a Thoughtful 2026 Oncology Conference Strategy
A well-considered oncology conference strategy in 2026 is not a list of events to attend. It is a deliberate allocation of time, budget, and senior talent across formats that serve different and genuinely distinct purposes.
Large clinical conferences such as ASCO and AACR are irreplaceable for scientific visibility, pipeline intelligence, and engagement with the research community. They are where clinical data is presented, where treatment paradigms are challenged or reinforced, and where the scientific credibility of products and organizations is built over time. For any company with an active oncology pipeline or scientific communications function, these events belong on the annual calendar.
Commercial and strategic conferences such as AMCP, Fierce Pharma Week, and the J.P. Morgan Healthcare Conference address different organizational needs. They serve market access, commercial strategy, investor relations, and business development functions that clinical conferences do not. For organizations that need to influence formulary decision-making, sharpen launch execution, or advance partnership conversations, these events fill a gap that scientific gatherings cannot.
Executive forums occupy a third and often underutilized position in the oncology conference landscape. The THMA Oncology Forum, Pharmacy Growth Collaborative, and CPE Circle are not substitutes for the events described above. They are complements to them, delivering something that neither large conferences nor commercial conferences are structurally able to provide direct, sustained, candid dialogue with the health system executives who translate scientific progress and commercial strategy into operational reality at the point of care. The intelligence generated in these settings is the connective tissue between everything else on the conference calendar.
The organizations that get the most from their 2026 oncology conference investment will be the ones that recognize these categories are not interchangeable and plan accordingly. That means attending ASCO for clinical intelligence, AMCP for payer access strategy, and THMA forums for the executive access and institutional relationships that convert intelligence into commercial outcomes.